Brought to you by 
Arpida closes CHF51.3mm third round; then an additional CHF33mm
19 Oct 2004
Executive Summary
Arpida Ltd. (develops anti-infectives) closed its third financing round, bringing in CHF51.3mm ($39mm). Returning investors Alta Berkeley, Aventic Partners, BioMedinvest, CDC IXIS Innovation, HBM BioVentures, HealthCap, 3i, and Partners Group were joined by Swissfirst Bank, Temasek Holdings, Carnegie Fund, CDIB Bioscience Ventures, CITA, MVI Finance, Schroder ISF, and other institutional and private investors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arpida closes CHF51.3mm third round; then an additional CHF33mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice